News
IBRX
6.39
-3.47%
-0.23
Weekly Report: what happened at IBRX last week (0708-0712)?
Weekly Report · 11h ago
CG Oncology Bringing Undervalued Innovation To Bladder Cancer
Seeking Alpha · 6d ago
ImmunityBio: All Eyes On Execution Now (Rating Upgrade)
Seeking Alpha · 6d ago
Weekly Report: what happened at IBRX last week (0701-0705)?
Weekly Report · 07/08 09:05
Chief Scientific Officer Patrick Soon-Shiong, ImmunityBio, Inc.'s (NASDAQ:IBRX) largest shareholder sees value of holdings go down 7.2% after recent drop
Insider shareholders of ImmunityBio, Inc. (NASDAQ:IBRX) have a 43% stake in the company. 62% of the business is held by the top 2 shareholders of the company, and 10% by institutions. The company has a significant amount of insider ownership of the stock. ImmunityBio's significant insider ownership suggests inherent interests in company's expansion. In the last 12 months, insiders lost US$339m of their stake in ImmunityBio. We look at the different ownership groups of immunityBio.
Simply Wall St · 07/04 14:41
Weekly Report: what happened at IBRX last week (0624-0628)?
Weekly Report · 07/01 09:05
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
NASDAQ · 06/26 13:41
ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential
Seeking Alpha · 06/25 19:44
Weekly Report: what happened at IBRX last week (0617-0621)?
Weekly Report · 06/24 09:06
China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
Mid-cap stocks were the best performers in the last week. Bilibili Inc. Shares rose 23.32% and Sasol Ltd. Shares escalated 20.89%. Ollie’s Bargain Outlet Holdings Inc. Stock gained 15.25% after JP Morgan upgraded the stock from Neutral to Overweight. ImmunityBio, Inc. Jumped 22.36% after insurance coverage of ANKTIVA.
Benzinga · 06/23 22:21
Notable Thursday Option Activity: UPS, IBRX, ABT
NASDAQ · 06/20 19:38
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Jabil Inc. Fell 7.8% to $116.37 on Thursday. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down 20.2% year-on-year. MGO Global, Inc. Shares jumped 222.8%.
Benzinga · 06/20 17:26
Why ImmunityBio Stock Is Trading Higher Thursday
ImmunityBio, Inc. Announced insurance coverage of ANKTIVA across multiple states. The immunotherapy is used to treat non-muscle invasive bladder cancer. The first doses of AN KTIVA have now been administered to patients across the United States. ANKT IVA received FDA approval less than two months ago.
Benzinga · 06/20 16:49
ImmunityBio spikes after commercial update on lead drug Anktiva
ImmunityBio (IBRX) recorded its biggest intraday gain since April. The company said multiple payors across the U.S. Have offered insurance coverage for its bladder cancer therapy, Anktiva. The drug was approved by the FDA in April.
Seeking Alpha · 06/20 16:28
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
Shares of KB Home rose 4.2% to $70.91 on Thursday. The company posted better-than-expected earnings and sales results for its second quarter on Tuesday. The Dow Jones index gained 150 points in Thursday's session. Ocular Therapeutix shares climbed 16% after Cowen upgraded the stock to Buy.
Benzinga · 06/20 14:21
ImmunityBio Announces Insurance Coverage of ANKTIVA Across Multiple States With First Commercial Doses Administered
Multiple patients treated across the U.S. With ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG unresponsive non-muscle invasive bladder cancer. Anktiva's novel mechanism of action activates the body's immune system of natural killer and killer T cells to attack BCG resistant tumor cells.
Benzinga · 06/20 13:17
IMMUNITYBIO ANNOUNCES INSURANCE COVERAGE OF ANKTIVA® ACROSS MULTIPLE STATES WITH FIRST COMMERCIAL DOSES ADMINISTERED JUST WEEKS AFTER FDA APPROVAL—OPENING NEW ERA FOR IMMUNOTHERAPY BEYOND CHECKPOINT INHIBITORS
Reuters · 06/20 13:00
Weekly Report: what happened at IBRX last week (0610-0614)?
Weekly Report · 06/17 09:05
Weekly Report: what happened at IBRX last week (0603-0607)?
Weekly Report · 06/10 09:05
IMMUNITYBIO ANNOUNCES 2024 ANNUAL MEETING OF STOCKHOLDERS WITH COMPANY UPDATE
Reuters · 06/07 13:13
More
Webull provides a variety of real-time IBRX stock news. You can receive the latest news about Immunitybio Inc through multiple platforms. This information may help you make smarter investment decisions.
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.